Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo-controlled, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of PMX205 in healthy volunteers

Next Previous
Trial Profile

A randomised, double-blind, placebo-controlled, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of PMX205 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALS 205 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Alsonex Pharmaceuticals

Most Recent Events

  • 09 Oct 2020 Status changed from not yet recruiting to recruiting.
  • 22 Apr 2020 Planned initiation date changed from 1 Mar 2020 to 11 May 2020.
  • 02 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top